NCT03203850View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 11, 2018

Primary Completion Date

April 17, 2023

Study Completion Date

April 17, 2023

Conditions
Hereditary Hemochromatosis
Interventions
DRUG

Deferasirox FCT

Taken orally once per day (QD) as a film coated tablet (FCT)

PROCEDURE

Phlebotomy

according to investigator's decision

Trial Locations (11)

3000

Novartis Investigative Site, Leuven

6900

Novartis Investigative Site, Lugano

35010

Novartis Investigative Site, Las Palmas de Gran Canaria

35043

Novartis Investigative Site, Rennes

48903

Novartis Investigative Site, Barakaldo

85107

Novartis Investigative Site, Bratislava

87042

Novartis Investigative Site, Limoges

125167

Novartis Investigative Site, Moscow

550245

Novartis Investigative Site, Sibiu

831 01

Novartis Investigative Site, Bratislava

08241

Novartis Investigative Site, Manresa

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY